Drug Profile
Nasapaque
Latest Information Update: 23 Aug 2017
Price :
$50
*
At a glance
- Originator 3E Therapeutics
- Developer Ora Inc
- Class Antiallergics; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 23 Aug 2017 No development reported - Phase-I/II for Allergic rhinitis in USA (Topical)
- 04 Mar 2016 Efficacy data from a phase I/II trial in Allergic rhinitis presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
- 29 Mar 2015 Phase-I/II clinical trials in Allergic rhinitis in USA (Topical) (NCT02377895)